stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Current ratio
Praxis Precision Medicines, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 15.7×, up 5.5× from fiscal 2025 (10.2×). Over the past ten years it has ranged from 3.2× (fiscal 2022) to 19.2× (fiscal 2020); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 10.2× | (5.09%) |
| FY2024 | 10.8× | 99.81% |
| FY2023 | 5.4× | 67.00% |
| FY2022 | 3.2× | (56.84%) |
| FY2021 | 7.5× | (61.12%) |
| FY2020 | 19.2× | 188.21% |
| FY2019 | 6.7× | 79.50% |
| FY2018 | 3.7× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 15.7× | (0.91%) |
| Mar 2026 | 15.9× | 55.36% |
| Dec 2025 | 10.2× | 97.38% |
| Sep 2025 | 5.2× | (17.90%) |
| 22 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | 27.4× |
| PRAX Praxis Precision Medicines, Inc. | 15.7× |
| KRYS Krystal Biotech, Inc. compare | 7.9× |
| ABVX Abivax SA Sponsored ADR compare | 6.0× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 5.9× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| CORT Corcept Therapeutics Incorporated compare | 3.0× |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 2.8× |
| AXSM Axsome Therapeutics, Inc. compare | 1.4× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)